Frontotemporal dementia: Recommendations for therapeutic studies, designs, and approaches

Canadian Journal of Neurological Sciences

Volumn 34, Issue SUPPL. 1, 2007, Pages

  Freedman, Morris ^a,b,c  

^a ROTMAN RESEARCH INSTITUTE   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMANTADINE; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; EDETATE CALCIUM; FLUOXETINE; FLUVOXAMINE; GALANTAMINE; GUANFACINE; IDAZOXAN; LITHIUM; METHYLPHENIDATE; MOCLOBEMIDE; MONOAMINE OXIDASE B INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PIRACETAM; PLACEBO; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE;

ALZHEIMER DISEASE; APHASIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DAILY LIFE ACTIVITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FRONTOTEMPORAL DEMENTIA; HUMAN; MINI MENTAL STATE EXAMINATION; NIEMANN PICK DISEASE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 34248513254     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100005680     Document Type: Conference Paper

References (70)

1. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998; 51:1546-54.
2. Hodges JR, Miller B. The classification, genetics and neuropathology of frontotemporal dementia. Introduction to the special topic papers: Part I. Neurocase. 2001; 7:31-5.
3. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the work group on frontotemporal dementia and Pick's disease. Arch Neurol. 2001; 58:1803-9.
4. Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002; 58:1615-21.
5. Ikeda M, Ishikawa T, Tanabe H. Epidemiology of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord. 2004; 17:265-8.
6. Gustafson L, Brun A. Frontal lobe degeneration of non-Alzheimer type and its relation to other frontotemporal dementias and Alzheimer's disease. In: Kertesz A, Munoz DG, editors. Pick's disease and Pick complex. Toronto: Wiley-Liss; 1998. p. 33-46.
7. Rosso SM, Donker Kaat L, Baks T, Joosee M, de Koning I, Pijnenburg Y, et al. Frontotemporal dementia in the Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain. 2003; 126:2016-22.
8. Imamura T, Hirono N, Hashimoto M, Shimomura T, Tanimukai S, Kazui H, et al. Clinical diagnosis of dementia with Lewy bodies in a Japanese dementia registry. Dement Geriatr Cogn Disord. 1999; 10:210-6.
9. Knopman DS, Mastri AR, Frey WH, Sung JH 2nd, Rustan T. Dementia lacking distinctive histological features: a common non-Alzheimer degenerative dementia. Neurology. 1990; 40:251-6.
10. Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Loewenstein D, et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord. 2002; 16:203-12.
11. Giannakopoulos P, Hof PR, Bouras C. Dementia lacking distinctive histopathology: clinicopathological evaluation of 32 cases. Acta Neuropathol (Berl). 1995; 89:346-55.
12. Brun A. Frontal lobe degeneration of non-Alzheimer type. I. Neuropathology. Arch Gerontol Geriatr. 1987; 6:193-208.
13. Sparks D L, Markesbery W R. Altered serotonergic and cholinergic synaptic markers in Pick's disease. Arch Neurol. 1991; 48:796-9.
14. Sjögren M, Minthon L, Passant U, Blennow K, Wallin A. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiol Aging. 1998; 19:379-84.
15. Proctor AW, Qurne M, Francis PT. Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord. 1999; 10:80-4.
16. Perry RJ, Miller BL. Behavior and treatment in frontotemporal dementia. Neurology. 2001; 56:S46-51.
17. Pasquier F, Fukui T, Sarazin M, Pijnenburg Y, Diehl J, Grundman M, et al. Laboratory investigations and treatment in frontotemporal dementia. Ann Neurol. 2003; 54:S32-5.
18. Sahakian BJ, Coull JJ, Hodges JR. Selective enhancement of executive function by idazoxan in a patient with dementia of the frontal lobe type. J Neurol Neurosurg Psychiatry. 1994; 57:120-1.
19. Coull JT, Sahakian BJ, Hodges JR. The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type. Psychopharmacology (Berl). 1996; 123:239-49.
20. Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomized, controlled trial with Trazodone. Dement Geriatr Cogn Disord. 2004; 17:355-9.
21. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl). 2004; 172:400-8.
22. Kertesz A, Blair M, Davidson W, Light M, Morlog D, Brashear R. A pilot study of the safety and efficacy of galantamine for Pick complex/frontotemporal dementia (FTD). Ann Neurol. 2005; 58:S47.
23. Rahman S, Robbins TW, Hodges JR, Mehta MA, Nestor PJ, Clark L, et al. Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsycho pharmacology. 2006; 31:651-8.
24. Gregory CA, Hodges JR. Dementia of frontal type and the focal lobar atrophies. Int Rev Psychiatry. 1993; 5:397-406.
25. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994;57:416-8.
26. Kertesz A. Pick's disease and Pick complex: introductory nosology. In: Kertesz A, Munoz DG, editors. Pick's disease and Pick complex. Toronto: Wiley-Liss; 1998. p. 1-11.
27. Lebert F, Pasquier F. Trazodone in the treatment of behavior in frontotemporal dementia. Hum Psychopharmacol Clin Exp. 1999; 14:279-81.
28. Anderson IM, Scott K, Harborne G. Serotonin and depression in frontal lobe dementia. Am J Psychiatry. 1995; 152:645.
29. Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors [erratum appears in J Clin Psychiatry 1997 Jun;58(6):275]. J Clin Psychiatry. 1997; 58:212-6.
30. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003; 49:13-9.
31. American Psychiatric Association. DSM-IV: Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994.
32. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation. Int J Geriatr Psychiatry. 2002; 17:391-2.
33. Adler G, Teufel M, Drach LM. Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int J Geriatr Psychiatry. 2003; 18:653-5.
34. Ikeda M, Shigenobu K, Fukuhara R, Hokoishi K, Maki N, Nebu A, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord. 2004; 17:117-21.
35. Shigenobu K, Ikeda M, Fukuhara R, Maki N, Hokoishi K, Nebu A, et al. The stereotypy rating inventory for frontotemporal lobar degeneration. Psychiatry Res. 2002; 110:175-87.
36. . Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004; 21:931-7.
37. Lampl Y, Sadeh M, Lorberboym M. Efficacy of acetylcholinesterase inhibitors in frontotemporal dementia. Ann Pharmacother. 2004; 38:1967-8.
38. Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2002; 17:267-72.
39. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003; 18:205-14.
40. Curtis RC, Resch DS. Case of Pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol. 2000; 20:384-5.
41. Drayton SJ, Davies K, Steinberg M, Leroi I, Rosenblatt A, Lyketsos CG. Amantadine for executive dysfunction syndrome in patients with dementia. Psychosomatics. 2004; 45:205-9.
42. Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord. 2005; 20:742-5.
43. Chow TW. Open label trial of guanfacine for symptomatic treatment of frontotemporal dementia. J Neuropsychiatry Clin Neurosci. 2002; 14:110.
44. Goforth HW, Konopka L, Primeau M, Ruth A, O'Donnell K, Patel R, et al. Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study. Clin EEG Neurosci. 2004; 35:108-11.
45. Lara DR, Cruz MR, Xavier F, Souza DO, Moriguchi EH. Allopurinol for the treatment of aggressive behaviour in patients with dementia. Int Clin Psychopharmacol. 2003; 18:53-5.
46. Imamura T, Takanashi M, Hattori N, Fujimori M, Yamashita H, Ishii K, et al. Bromocriptine treatment for perseveration in demented patients. Alzheimer Dis Assoc Disord. 1998; 12:109-13.
47. Richard J, Constantinidis J, Tissot R. Calcium EDTA treatment of Pick's disease. Nouv Presse Med. 1978; 7:1304.
48. Constantinidis J, Tissot R. Role of glutamate and zinc in the hippocampal lesions of Pick's disease. Adv Biochem Psychopharmacol. 1981; 27:413-22.
49. Richard J, Constantinidis J, Tissot R. Maladie de PICK et metabolisme du zinc. Arguments pour une nouvelle hypothese pathogenique et premiers resultats d'un traitement prolonge par l'EDTA calcique. In: Muller C, Wertheimer J, editors. Gerontopsychiatrie 7. Janssen Pharmaceutica; 1979. p. 83-8.
50. Gregory CA, Serra-Mestres J, Hodges JR. Early diagnosis of the frontal variant of frontotemporal dementia: how sensitive are standard neuroimaging and neuropsychologic tests? Neuropsychiatry Neuropsychol Behav Neurol. 1999; 12:128-35.
51. Gregory C, Lough S, Stone V, Erzinclioglu S, Martin L, Baron-Cohen S, et al. Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer's disease: theoretical and practical implications. Brain. 2002; 125:752-64.
52. Freedman M, Black S, Ebert P, Binns M. Orbitofrontal function, object alternation and perseveration. Cereb Cortex. 1998; 8:18-27.
53. Freedman M, Binns MA, Black SE, Levine B, Miller B, Stuss DT. Object Alternation: A cognitive and diagnostic measure of orbitofrontal function in frontotemporal dementia. Neurology. 2003; Suppl 1:A264.
54. Royall DR, Mahurin RK, Gray KF. Bedside assessement of executive cognitive impairment: The executive interview. J Am Geriatr Soc. 1992; 40:1221-6.
55. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: A frontal assessment battery at bedside. Neurology. 2000; 55:1621-6.
56. Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR. A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology. 2000; 55:1613-20.
57. Heaton RK. Wisconsin Card Sorting Test Manual. Florida: Psychological Assessment Resources Inc., 1981.
58. Freedman M, Leach L, Kaplan E, Winocur G, Shulman KI, Delis D. Clock drawing: a neuropsychological analysis. New York: Oxford University Press 1994.
59. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44:2308-14.
60. Kertesz A, Davidson W, Fox H. Frontal behavioral inventory: Diagnostic criteria for frontal lobe dementia. Can J Neurol Sci. 1997; 24:29-36.
61. Kertesz A, Nadkarni N, Davidson W, Thomas AW. The frontal behavioral inventory in the differential diagnosis of frontotemporal dementia. J Int Neuropsychol Soc. 2000; 6:460-8.
62. Kertesz A, Davidson W, McCabe P, Munoz D. Behavioral quantitation is more sensitive than cognitive testing in frontotemporal dementia. Alzheimer Dis Assoc Disord. 2003; 17:223-9.
63. Grace J, Stout JC, Malloy PF. Assessing frontal lobe behavioral syndromes with The Frontal Lobe Personality Scale. Assessment. 1999; 6:269-84.
64. Stout JC, Ready RE, Grace J, Malloy PF, Paulsen JS. Factor analysis of the frontal systems behavior scale (FrSBe). Assessment. 2003; 10:79-85.
65. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 1999; 53:471-81.
66. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. Alzheimer Dis Assoc Disord. 1997; 11:S22-32.
67. Kaufer DI, Cummings JL, Christine D, Bray T, Castellon S, Masterman D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the neuropsychiatric inventory caregiver distress scale. J Am Geriatr Soc. 1998; 46:210-5.
68. Greene JG, Smith R, Gardiner M, Timbury GC. Measuring behavioral disturbance of elderly demented patients in the community and its effects on relatives: a factor analytic study. Age Ageing. 1982; 11:121-6.
69. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982; 140:566-72.
70. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993; 43:2412-4.